title: Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
authors: Department of Internal Medicine Hospital Central de la Defensa Madrid, Spain javimembrillo@gmail.com Department of Cardiology Hospital Central de la Defensa Madrid, Spain Department of Rheumatology Hospital Universitario de la Princesa Madrid, Spain Department of Internal Medicine Hospital Central de la Defensa Madrid, Spain Department of Cardiology Hospital Central de la Defensa Madrid, Spain Department of Internal Medicine Hospital Central de la Defensa Madrid, Spain.
authors: Francisco Javier
authors: FJ
authors: Membrillo de Novales
authors: Alberto
authors: A
authors: Ávila Jiménez
authors: Leticia
authors: L
authors: Merino Meléndez
authors: Juan
authors: J
authors: Torres León
authors: Edurne
authors: E
authors: López Soberón
authors: Antonio
authors: A
authors: Fe Marqués
authors: Julio Francisco
authors: JF
authors: Pérez Mochales
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced* / Q000175:diagnosis* / Q000000981:diagnostic imaging; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004452:Echocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy; D012720:Severity of Illness Index; D000069549:Ustekinumab / Q000009:adverse effects* / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D000069549:Ustekinumab; D000068879:Adalimumab